Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine, Oxaliplatin, Bevacizumab and Radiation in Biliary Tract Cancer
NCT00142480Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2004
- Primary completion
- Jul 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in biliary tract cancer (BTC) and gallbladder adenocarcinoma, sponsored by Massachusetts General Hospital. Primary endpoint: Progression Free Survival Rate at 1 year. Started Dec 2004; status: completed.
02
Drugs
bevacizumab
03
Conditions
biliary tract cancer (BTC)gallbladder adenocarcinoma
Beyond the preview
Go deeper on NCT00142480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00142480.